In highly Covid-19 (C-19) vaccinated populations, the immune escape pandemic is now on the brink of shifting from its chronic phase (noncognate T cell-dependent immune pathology leading to long Covid) to its hyperacute phase (antibody-dependent enhancement of severe disease). This could soon trigger a tsunami of death in these highly vaccinated populations. However, those who are healthy and unvaccinated will not be affected. My sincere hope is that the prophylactic use of safe and effective antivirals by C-19 vaccinees who experienced symptomatic breakthrough infection following exposure to Omicron (descendants), individuals who recovered from severe C-19 disease after natural infection, or those vaccinated following symptomatic infection will prevent such a catastrophe. However, since no single expert or influential authority believes me, society in highly C-19 vaccinated countries will likely be caught off guard.
“There is no greater impotence in all the world like knowing you are right and that the wave of the world is wrong, yet the wave crashes upon you.”
– Norman Mailer
Geert Vanden Bossche received his DVM from the University of Ghent, Belgium, and his PhD degree in Virology from the University of Hohenheim, Germany. He held adjunct faculty appointments at universities in Belgium and Germany. After his career in Academia, Geert joined several vaccine companies (GSK Biologicals, Novartis Vaccines, Solvay Biologicals) to serve various roles in vaccine R&D as well as in late vaccine development.
Geert then moved on to join the Bill & Melinda Gates Foundation’s Global Health Discovery team in Seattle (USA) as Senior Program Officer; he then worked with the Global Alliance for Vaccines and Immunization (GAVI) in Geneva as Senior Ebola Program Manager. At GAVI he tracked efforts to develop an Ebola vaccine. He also represented GAVI in fora with other partners, including WHO, to review progress on the fight against Ebola and to build plans for global pandemic preparedness.
Back in 2015, Geert scrutinized and questioned the safety of the Ebola vaccine that was used in ring vaccination trials conducted by WHO in Guinea. His critical scientific analysis and report on the data published by WHO in the Lancet in 2015 was sent to all international health and regulatory authorities involved in the Ebola vaccination program. After working for GAVI, Geert joined the German Center for Infection Research in Cologne as Head of the Vaccine Development Office. He is at present primarily serving as a Biotech / Vaccine consultant while also conducting his own research on Natural Killer cell-based vaccines.
Email: info@voiceforscienceandsolidarity.org
.svg){kind=small}
